<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920242</url>
  </required_header>
  <id_info>
    <org_study_id>1526 RIF_2</org_study_id>
    <nct_id>NCT02920242</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared safety and efficacy of a generic rifaximin tablet to the reference listed
      drug in the treatment of travelers' diarrhea. Additionally both the generic and reference
      formulations were tested for superiority against a placebo tablet.

      It was planned that 450 patients would be enrolled, but only 28 patients were randomized. Of
      these, 1 patient discontinued due to failure to meet the inclusion/exclusion criteria. The
      remaining 27 patients received study drug and 25 patients completed the study.

      The study was terminated due to slow enrolment. The final analysis included only safety
      analysis in the Safety population, due to the low number of randomized patients. No efficacy
      analysis was performed.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to low enrollment
  </why_stopped>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Actual">May 23, 2017</completion_date>
  <primary_completion_date type="Actual">May 23, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure Rate</measure>
    <time_frame>study day 5 +/- 1 day</time_frame>
    <description>Clinical cure was defined as either no stools or only formed stools within a 48 hour period and no fever, with or without other enteric symptoms, OR no watery stools or no more than two soft stools passed within a 24 hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Last Unformed Stool</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Clinical Failure</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Improvement of Diarrheal Syndrome</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Unformed Stools</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Presence or Absence and Severity of Signs and Symptoms of Enteric Infection</measure>
    <time_frame>within 5 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Cure Rate</measure>
    <time_frame>study day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Travelers' Diarrhea</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xifaxan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received placebo tablet 3 times per day for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin (Sandoz GmbH) tablet</intervention_name>
    <description>200 mg tablet administered orally.</description>
    <arm_group_label>Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin (Xifaxan)</intervention_name>
    <description>200 mg tablet administered orally</description>
    <arm_group_label>Xifaxan</arm_group_label>
    <other_name>Xifaxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo tablet administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is able to read and understood the language of the Informed Consent Form and
             Patient Information.

          -  International travelers with a duration of stay in host country long enough to attend
             schedules visits.

          -  Affected by naturally acquired acute diarrhea, defined as the passage of at least 3
             unformed stools within 24 hours immediately preceding randomization preceding
             randomization

        Exclusion Criteria:

          -  Hypersensitivity to rifaximin or any of the rifamycin antimicrobial agents or to any
             of the excipients of the study drug.

          -  Pregnant, breast feeding or planning pregnancy

          -  Acute diarrhea for &gt; 72 hours immediately prior to randomization.

          -  Presence of fever (≥ 100 °F/37.8°C) or hematochezia (blood in stool, noted visually)
             or clinical findings suggesting moderate or severe dehydration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <results_first_submitted>April 27, 2018</results_first_submitted>
  <results_first_submitted_qc>December 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2019</results_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Travelers</keyword>
  <keyword>diarrhea</keyword>
  <keyword>rifaximin</keyword>
  <keyword>equivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02920242/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02920242/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rifaximin</title>
          <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
        </group>
        <group group_id="P2">
          <title>Xifaxan</title>
          <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Patients received placebo tablet 3 times per day for 3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet inc./exc. criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics was based on the safety analysis set.</population>
      <group_list>
        <group group_id="B1">
          <title>Rifaximin</title>
          <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
        </group>
        <group group_id="B2">
          <title>Xifaxan</title>
          <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Patients received placebo tablet 3 times per day for 3 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="18.27"/>
                    <measurement group_id="B2" value="38.2" spread="18.69"/>
                    <measurement group_id="B3" value="35.8" spread="21.93"/>
                    <measurement group_id="B4" value="37.0" spread="18.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cure Rate</title>
        <description>Clinical cure was defined as either no stools or only formed stools within a 48 hour period and no fever, with or without other enteric symptoms, OR no watery stools or no more than two soft stools passed within a 24 hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence.</description>
        <time_frame>study day 5 +/- 1 day</time_frame>
        <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Xifaxan</title>
            <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients received placebo tablet 3 times per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure Rate</title>
          <description>Clinical cure was defined as either no stools or only formed stools within a 48 hour period and no fever, with or without other enteric symptoms, OR no watery stools or no more than two soft stools passed within a 24 hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence.</description>
          <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Last Unformed Stool</title>
        <time_frame>within 5 study days</time_frame>
        <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Xifaxan</title>
            <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients received placebo tablet 3 times per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Last Unformed Stool</title>
          <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Clinical Failure</title>
        <time_frame>within 5 study days</time_frame>
        <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Xifaxan</title>
            <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients received placebo tablet 3 times per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Clinical Failure</title>
          <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Improvement of Diarrheal Syndrome</title>
        <time_frame>within 5 study days</time_frame>
        <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Xifaxan</title>
            <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients received placebo tablet 3 times per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Improvement of Diarrheal Syndrome</title>
          <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unformed Stools</title>
        <time_frame>within 5 study days</time_frame>
        <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Xifaxan</title>
            <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients received placebo tablet 3 times per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unformed Stools</title>
          <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Presence or Absence and Severity of Signs and Symptoms of Enteric Infection</title>
        <time_frame>within 5 study days</time_frame>
        <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Xifaxan</title>
            <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients received placebo tablet 3 times per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Presence or Absence and Severity of Signs and Symptoms of Enteric Infection</title>
          <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Cure Rate</title>
        <time_frame>study day 5</time_frame>
        <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifaximin</title>
            <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Xifaxan</title>
            <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients received placebo tablet 3 times per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Cure Rate</title>
          <population>The study was terminated after only 28 patients (6% of planned population) were randomized. In line with the predefined Statistical Analysis Plan (SAP) no efficacy analysis was performed due to low sample size.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to day 5 +/- 1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rifaximin</title>
          <description>Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.</description>
        </group>
        <group group_id="E2">
          <title>Xifaxan</title>
          <description>Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Patients received placebo tablet 3 times per day for 3 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-1873</phone>
      <email>novartisemail@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

